Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimer's Disease Research and Development

  Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimer's
                       Disease Research and Development

Investment is an Important Advancement in the Company's Long-term Commitment
to Bringing New Medicines to Millions of Alzheimer's Disease Patients Who Are

PR Newswire

INDIANAPOLIS, April 17, 2013

INDIANAPOLIS, April 17, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
today announced it has acquired two investigational positron emission
tomography (PET) tracers from Siemens Medical Solutions USA, Inc. The tracers
are intended to image tau (or neurofibrillary) tangles in the brain, one of
two known hallmarks of Alzheimer's disease. Based on studies of samples
obtained at autopsy, the amount and location of tau tangles in an Alzheimer's
disease patient's brain is thought to correlate with the severity of the
disease. There are currently no approved diagnostics to detect tau tangles in
living patients, creating challenges for scientists working to understand the
progression of the disease and how therapies may impact it.

Lilly will initially focus on incorporating this new technology into its
anti-amyloid and anti-tau research and development (R&D) programs. Use of a
tau tangle tracer could enable tailoring and early identification of at-risk
patients, as well as potentially provide a marker for treatment response.
Lilly also has the option to commercialize the tracers. The tracers will be
developed and validated by a team at Avid Radiopharmaceuticals, Lilly's wholly
owned subsidiary focused on molecular imaging. Financial terms of the deal are
not being disclosed.

"The acquisition of these tau tangle tracers builds on our 25-year commitment
of investing in Alzheimer's disease research and development to bring new
medicines to patients facing the terrible consequences of Alzheimer's
disease," said Jan M. Lundberg, Ph.D., executive vice president, science and
technology, and president, Lilly Research Laboratories. "We are hopeful that
this technology will both enhance our understanding of tau and its role in
Alzheimer's disease, and contribute to the development of our anti-amyloid and
anti-tau based therapies to treat this disease."

"PET imaging is a valuable tool in the fight against Alzheimer's disease, and
Siemens is committed to helping fight this growing threat to our aging
population," said James Williams, CEO, Siemens Molecular Imaging business
unit. "Lilly's continued development of these tau PET tracers combined with
Siemens' ongoing investment in innovative PET imaging solutions is another
great example of how Siemens is collaborating with pharmaceutical companies in
an effort to provide new hope to patients and their families."

There are two defining pathologies linked to the development of Alzheimer's
disease: the accumulation of amyloid-beta protein that forms beta-amyloid
plaques outside of neurons, and the accumulation of tau protein that forms tau
tangles inside them.The formation of tau tangles is thought to block the
transport of nutrients and essential molecules throughout the cell, leading to
neurodegeneration, or the progressive loss of structure or function of
neurons. The formation of tau tangles mostly occurs after beta-amyloid plaques
have developed, but unlike beta-amyloid plaques the evolution of tau tangle
pathology is believed to closely mirror cognitive decline.

Scientists theorize that both beta-amyloid plaques and tau tangles are
required for the development of Alzheimer's disease, with the accumulation of
amyloid beta representing the early trigger that initiates the disease process
and tau tangles playing a secondary but critical role in the process of
neuronal toxicity and death. For this reason, Lilly has established R&D
programs to explore both the amyloid and tau hypotheses. Today's acquisition
will inform and help progress Lilly's multiple approaches to treating
Alzheimer's disease, with the goal of speeding innovation to patients

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers –
through medicines and information – for some of the world's most urgent
medical needs. Additional information about Lilly is available at

This press release contains forward-looking statements about the potential
benefits of Lilly's acquisition of two novel tau tangle PET tracers from
Siemens, and the potential for these tracers for use in the research and
development of treatments for Alzheimer's disease. It reflectsLilly's and
Siemens' current beliefs; however, as with any pharmaceutical product or
diagnostic tool, there are substantial risks and uncertainties in the process
of research, development, and commercialization. Further, there is no
guarantee that theLillywill realize the expected benefits of the
acquisition, that the acquired PET tracers will be commercialized, or that the
use of the tracers will further Lilly's research or progress in working to
discover a potential treatment for Alzheimer's disease. For further discussion
of these and other risks and uncertainties, please seeLilly's latest Forms
10-Q and 10-K filed with theU.S. Securities and Exchange Commission. The
companies undertake no duty to update forward-looking statements.


Refer to: Eva Groves, 1-317-224-4642 or

(Logo: )

SOURCE Eli Lilly and Company

Press spacebar to pause and continue. Press esc to stop.